Buyers eye Relypsa and its hyperkalemia drug

Eric Palmer Redwood City, CA-based Relypsa has hired an investment bank to check out M&A offers, Reuters reported. Relypsa isn't commenting but the news service says several ...

Allergan takes Linzess on a run with differentiation push

Carly Helfand Every drugmaker wants to find differentiators for their products. And for Ironwood, it was obvious. "Is this a constipation drug that improves abdominal symptoms, ...

A-listers provide a $50M B round to AstraZeneca’s antibiotics spinout Entasis

John Carroll Last summer, AstraZeneca formally spun out its pared-down early-stage antibiotics unit in Waltham, MA, as Entasis Therapeutics, bequeathing a $ 40 million A round for ...

FDA leaves biosim trial data off product labels in new guidance

Carly Helfand The FDA is out with new guidance for labeling biosimilar drugs–and it may not make some drugmakers happy. Regulators dismissed pharma's request that ...

Merck sets $54K list price for hep C combo as it preps for battle with Gilead, AbbVie

Carly Helfand Industry watchers have long been speculating on how Merck would take on heavyweights Gilead and AbbVie when it priced its new hep C regimen. And now, they have their answer: ...

Venetoclax grabs third FDA ‘breakthrough’ for blood cancer

Alok Saboo AbbVie and Roche's venetoclax has received yet another accelerated review from the FDA–this time in patients with the most common type of acute leukemia. FierceBiotech ...

Merck lines up for a quick approval with its C. diff therapy

Damian Garde Merck is nearing FDA approval for its Clostridium difficile-fighting antibody, picking up the agency's priority review designation with the promise of a shortened vetting ...

Langer-backed biotech reboots with $38M, new name and new cancer drug tech

John Carroll Four-year-old biotech Blend Therapeutics, launched with the scientific backing of MIT's Robert Langer and colleagues, is jettisoning its one-time lead drug program ...

Codiak piles on more venture cash, amassing $92M for exosome R&D

Damian Garde Startup Codiak BioSciences got off the ground in November with ambitious plans to turn exosomes into cancer therapies and venture commitments totaling more than $ 80 million. ...

Amgen’s Humira biosimilar nears FDA nod, but legal hurdles remain

Damian Garde Amgen's take on AbbVie's top-selling inflammation treatment is in line for FDA approval this year, but a patent fight between the two companies could keep it off ...

Novo Nordisk rolls out long-awaited Tresiba, aiming for blockbuster market share

Tracy Staton Novo Nordisk finally launched its next-gen diabetes treatment Tresiba in the U.S., approved by the FDA last September. The Danish drugmaker has high hopes ...

Soon-Shiong’s NantCell raises another $57M for immuno-oncology work

Damian Garde Billionaire entrepreneur Patrick Soon-Shiong's NantCell raised $ 57.3 million in equity to fund its work on treatments that use the immune system to fight cancer, ...
Page 1 of 20412345...102030...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS